M Richardson1, J Kirkham1, K Dwan2, D J Sloan3, G Davies4, A L Jorgensen1. 1. Department of Biostatistics, University of Liverpool, Liverpool. 2. Cochrane Editorial Unit, London. 3. School of Medicine, University of St Andrews, St Andrews. 4. Department of Clinical Infection, Microbiology and Immunology, University of Liverpool, Liverpool, UK.
Abstract
BACKGROUND: Tuberculosis (TB) patients receiving anti-tuberculosis treatment may experience serious adverse drug reactions (ADRs) such as hepatotoxicity. Variants of the N-acetyltransferase 2 (NAT2) gene may increase the risk of experiencing such toxicity events. OBJECTIVE: To provide a comprehensive evaluation of the evidence base for associations between NAT2 variants and anti-tuberculosis drug-related toxicity. METHOD: This was a systematic review and meta-analysis. We searched for studies in Medline, PubMed, EMBASE, BIOSIS and Web of Science. We included data from 41 articles (39 distinct cohorts of patients). We pooled effect estimates for each genotype on each outcome using meta-analyses stratified by country. RESULTS: We assessed the quality of the included studies, which was variable, with many areas of concern. Slow/intermediate NAT2 acetylators were statistically significantly more likely to experience hepatotoxicity than rapid acetylators (OR 1.59, 95%CI 1.26-2.01). Heterogeneity was not detected in the overall pooled analysis (I² = 0%). NAT2 acetylator status was significantly associated with the likelihood of experiencing anti-tuberculosis drug-related hepatotoxicity. CONCLUSION: We encountered several challenges in performing robust syntheses of data from pharmacogenetic studies, and we outline recommendations for the future reporting of pharmacogenetic studies to enable high-quality systematic reviews and meta-analyses to be performed.
BACKGROUND:Tuberculosis (TB) patients receiving anti-tuberculosis treatment may experience serious adverse drug reactions (ADRs) such as hepatotoxicity. Variants of the N-acetyltransferase 2 (NAT2) gene may increase the risk of experiencing such toxicity events. OBJECTIVE: To provide a comprehensive evaluation of the evidence base for associations between NAT2 variants and anti-tuberculosis drug-related toxicity. METHOD: This was a systematic review and meta-analysis. We searched for studies in Medline, PubMed, EMBASE, BIOSIS and Web of Science. We included data from 41 articles (39 distinct cohorts of patients). We pooled effect estimates for each genotype on each outcome using meta-analyses stratified by country. RESULTS: We assessed the quality of the included studies, which was variable, with many areas of concern. Slow/intermediate NAT2 acetylators were statistically significantly more likely to experience hepatotoxicity than rapid acetylators (OR 1.59, 95%CI 1.26-2.01). Heterogeneity was not detected in the overall pooled analysis (I² = 0%). NAT2 acetylator status was significantly associated with the likelihood of experiencing anti-tuberculosis drug-related hepatotoxicity. CONCLUSION: We encountered several challenges in performing robust syntheses of data from pharmacogenetic studies, and we outline recommendations for the future reporting of pharmacogenetic studies to enable high-quality systematic reviews and meta-analyses to be performed.
Authors: Alma Tostmann; Martin J Boeree; Rob E Aarnoutse; Wiel C M de Lange; Andre J A M van der Ven; Richard Dekhuijzen Journal: J Gastroenterol Hepatol Date: 2007-11-06 Impact factor: 4.029
Authors: Jussi J Saukkonen; David L Cohn; Robert M Jasmer; Steven Schenker; John A Jereb; Charles M Nolan; Charles A Peloquin; Fred M Gordin; David Nunes; Dorothy B Strader; John Bernardo; Raman Venkataramanan; Timothy R Sterling Journal: Am J Respir Crit Care Med Date: 2006-10-15 Impact factor: 21.405
Authors: L Ben Mahmoud; H Ghozzi; A Kamoun; A Hakim; H Hachicha; S Hammami; Z Sahnoun; N Zalila; H Makni; K Zeghal Journal: Pathol Biol (Paris) Date: 2012-10
Authors: M Ohno; I Yamaguchi; I Yamamoto; T Fukuda; S Yokota; R Maekura; M Ito; Y Yamamoto; T Ogura; K Maeda; K Komuta; T Igarashi; J Azuma Journal: Int J Tuberc Lung Dis Date: 2000-03 Impact factor: 2.373
Authors: Julian Little; Julian P T Higgins; John P A Ioannidis; David Moher; France Gagnon; Erik von Elm; Muin J Khoury; Barbara Cohen; George Davey-Smith; Jeremy Grimshaw; Paul Scheet; Marta Gwinn; Robin E Williamson; Guang Yong Zou; Kim Hutchings; Candice Y Johnson; Valerie Tait; Miriam Wiens; Jean Golding; Cornelia van Duijn; John McLaughlin; Andrew Paterson; George Wells; Isabel Fortier; Matthew Freedman; Maja Zecevic; Richard King; Claire Infante-Rivard; Alex Stewart; Nick Birkett Journal: Hum Genet Date: 2009-02-01 Impact factor: 4.132
Authors: L G Possuelo; J A Castelan; T C de Brito; A W Ribeiro; P I Cafrune; P D Picon; A R Santos; R L F Teixeira; T S Gregianini; M H Hutz; M L R Rossetti; A Zaha Journal: Eur J Clin Pharmacol Date: 2008-04-18 Impact factor: 2.953
Authors: Maria João Cavaco; Celeste Alcobia; Bárbara Oliveiros; Luís Alcides Mesquita; Aurora Carvalho; Fernando Matos; José Miguel Carvalho; Miguel Villar; Raquel Duarte; João Mendes; Carolina Ribeiro; Carlos Robalo Cordeiro; Fernando Regateiro; Henriqueta Coimbra Silva Journal: J Pers Med Date: 2022-05-13
Authors: J W C Alffenaar; S L Stocker; L Davies Forsman; A Garcia-Prats; S K Heysell; R E Aarnoutse; O W Akkerman; A Aleksa; R van Altena; W Arrazola de Oñata; P K Bhavani; N Van't Boveneind-Vrubleuskaya; A C C Carvalho; R Centis; J M Chakaya; D M Cirillo; J G Cho; L D Ambrosio; M P Dalcolmo; P Denti; K Dheda; G J Fox; A C Hesseling; H Y Kim; C U Köser; B J Marais; I Margineanu; A G Märtson; M Munoz Torrico; H M Nataprawira; C W M Ong; R Otto-Knapp; C A Peloquin; D R Silva; R Ruslami; P Santoso; R M Savic; R Singla; E M Svensson; A Skrahina; D van Soolingen; S Srivastava; M Tadolini; S Tiberi; T A Thomas; Z F Udwadia; D H Vu; W Zhang; S G Mpagama; T Schön; G B Migliori Journal: Int J Tuberc Lung Dis Date: 2022-06-01 Impact factor: 3.427
Authors: Luis Jaramillo-Valverde; Kelly S Levano; David D Tarazona; Silvia Capristano; Roberto Zegarra-Chapoñan; Cesar Sanchez; Velia M Yufra-Picardo; Eduardo Tarazona-Santos; Cesar Ugarte-Gil; Heinner Guio Journal: Mol Genet Genomic Med Date: 2022-06-24 Impact factor: 2.473
Authors: Neil E Rens; Carin A Uyl-de Groot; Jeremy D Goldhaber-Fiebert; Julio Croda; Jason R Andrews Journal: Clin Infect Dis Date: 2020-12-15 Impact factor: 9.079